Exact Sciences (EXAS) Stock Forecast, Price Target & Predictions
EXAS Stock Forecast
Exact Sciences stock forecast is as follows: an average price target of $89.67 (represents a 76.07% upside from EXAS’s last price of $50.93) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.
EXAS Price Target
The average price target for Exact Sciences (EXAS) is $89.67 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $168.00 to $60.00. This represents a potential 76.07% upside from EXAS's last price of $50.93.
EXAS Analyst Ratings
According to 17 Wall Street analysts, Exact Sciences's rating consensus is 'Buy'. The analyst rating breakdown for EXAS stock is 1 'Strong Buy' (5.88%), 15 'Buy' (88.24%), 1 'Hold' (5.88%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Exact Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 06, 2024 | Catherine Schulte | Robert W. Baird | $67.00 | $72.42 | -7.48% | 31.55% |
| Nov 06, 2024 | Mark Massaro | BTIG | $65.00 | $72.42 | -10.25% | 27.63% |
| Oct 29, 2024 | Kyle Mikson | Canaccord Genuity | $95.00 | $69.35 | 36.99% | 86.53% |
| Oct 01, 2024 | Vijay Kumar | Evercore ISI | $80.00 | $68.12 | 17.44% | 57.08% |
| Sep 16, 2024 | Mark Massaro | BTIG | $82.00 | $69.48 | 18.02% | 61.01% |
| Sep 16, 2024 | Patrick Donnelly | Citigroup | $80.00 | $67.90 | 17.82% | 57.08% |
| Sep 13, 2024 | Kyle Mikson | Canaccord Genuity | $75.00 | $67.39 | 11.29% | 47.26% |
| Sep 12, 2024 | David Westenberg | Piper Sandler | $85.00 | $66.93 | 27.00% | 66.90% |
| Jul 19, 2024 | David Westenberg | Piper Sandler | $80.00 | $46.81 | 70.90% | 57.08% |
| Jun 26, 2024 | Sung Ji Nam | Scotiabank | $70.00 | $44.16 | 58.51% | 37.44% |
The latest Exact Sciences stock forecast, released on Nov 06, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $67.00, which represents a -7.48% decrease from the stock price at the time of the forecast ($72.42), and a 31.55% increase from EXAS last price ($50.93).
Exact Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 8 | 13 |
| Avg Price Target | $75.67 | $78.63 | $77.62 |
| Last Closing Price | $50.93 | $50.93 | $50.93 |
| Upside/Downside | 48.58% | 54.39% | 52.41% |
In the current month, the average price target of Exact Sciences stock is $75.67, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 48.58% increase as opposed to Exact Sciences's last price of $50.93. This month's average price target is down -3.76% compared to last quarter, and down -2.51% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 29, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Oct 29, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Oct 04, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Oct 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 01, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 16, 2024 | BTIG | Buy | Buy | Hold |
| Sep 16, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 13, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Exact Sciences's last stock rating was published by Wells Fargo on Oct 29, 2024. The company gave EXAS a "Buy" rating, the same as its previous rate.
Exact Sciences Financial Forecast
Exact Sciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $628.34M | $622.09M | $602.45M | $553.00M | $523.07M | $521.64M | $486.57M | $473.81M | $456.38M | $434.82M | $402.08M | $466.34M | $408.36M | $268.87M | $347.82M | $295.57M | $218.81M |
| Avg Forecast | $893.23M | $870.11M | $854.14M | $785.30M | $800.46M | $785.59M | $764.88M | $702.49M | $694.91M | $716.80M | $690.02M | $627.35M | $638.83M | $616.79M | $601.14M | $543.45M | $527.21M | $501.70M | $498.99M | $463.11M | $449.11M | $430.03M | $420.98M | $388.57M | $443.96M | $337.43M | $228.42M | $349.13M | $297.43M | $216.12M |
| High Forecast | $961.80M | $936.91M | $919.71M | $845.58M | $861.91M | $845.90M | $823.60M | $730.37M | $760.73M | $717.02M | $690.02M | $627.35M | $654.37M | $624.98M | $647.28M | $585.17M | $567.69M | $501.70M | $498.99M | $463.11M | $449.11M | $430.03M | $420.98M | $388.57M | $443.96M | $337.43M | $228.42M | $349.13M | $297.43M | $216.12M |
| Low Forecast | $875.58M | $852.92M | $837.26M | $769.77M | $784.64M | $770.06M | $749.76M | $691.76M | $680.42M | $716.59M | $690.02M | $627.35M | $631.20M | $609.68M | $589.25M | $532.71M | $516.79M | $501.70M | $498.99M | $463.11M | $449.11M | $430.03M | $420.98M | $388.57M | $443.96M | $337.43M | $228.42M | $349.13M | $297.43M | $216.12M |
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 15 | 7 | 3 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 7 | 7 | 9 | 8 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.03% | 1.11% | 1.05% | 1.04% | 1.05% | 1.05% | 1.05% | 1.06% | 1.03% | 1.03% | 1.05% | 1.21% | 1.18% | 1.00% | 0.99% | 1.01% |
Exact Sciences's average Quarter revenue forecast for Dec 23 based on 7 analysts is $638.83M, with a low forecast of $631.20M, and a high forecast of $654.37M. EXAS's average Quarter revenue forecast represents a 1.67% increase compared to the company's last Quarter revenue of $628.34M (Sep 23).
Exact Sciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 15 | 7 | 3 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 7 | 7 | 9 | 8 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $72.03M | $-76.93M | $-54.52M | $-92.54M | $-84.99M | $-102.56M | $-130.75M | $-176.51M | $-121.36M | $-124.34M | $-225.66M | $-375.24M | $-158.79M | $-24.18M | $-51.71M | $-66.92M | $-17.41M |
| Avg Forecast | $-216.74M | $-211.13M | $-207.25M | $-190.55M | $-194.22M | $-190.62M | $-185.59M | $-170.45M | $-168.61M | $-173.93M | $-167.43M | $-164.50M | $-155.01M | $-149.66M | $-145.86M | $-149.54M | $-149.36M | $-121.90M | $-121.24M | $-135.95M | $-109.12M | $-104.49M | $-102.29M | $-370.69M | $-107.87M | $-81.99M | $-55.50M | $-41.19M | $-72.27M | $-52.51M |
| High Forecast | $-212.45M | $-206.95M | $-203.15M | $-186.78M | $-190.39M | $-186.85M | $-181.92M | $-167.85M | $-165.10M | $-173.87M | $-167.43M | $-131.60M | $-153.16M | $-147.93M | $-142.98M | $-119.63M | $-119.49M | $-121.90M | $-121.24M | $-108.76M | $-109.12M | $-104.49M | $-102.29M | $-296.55M | $-107.87M | $-81.99M | $-55.50M | $-32.95M | $-72.27M | $-52.51M |
| Low Forecast | $-233.37M | $-227.33M | $-223.16M | $-205.17M | $-209.13M | $-205.25M | $-199.84M | $-177.22M | $-184.58M | $-173.98M | $-167.43M | $-197.39M | $-158.78M | $-151.65M | $-157.06M | $-179.45M | $-179.23M | $-121.90M | $-121.24M | $-163.14M | $-109.12M | $-104.49M | $-102.29M | $-444.83M | $-107.87M | $-81.99M | $-55.50M | $-49.43M | $-72.27M | $-52.51M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.48% | 0.53% | 0.36% | 0.62% | 0.70% | 0.85% | 0.96% | 1.62% | 1.16% | 1.22% | 0.61% | 3.48% | 1.94% | 0.44% | 1.26% | 0.93% | 0.33% |
7 analysts predict EXAS's average Quarter EBITDA for Dec 23 to be $-155.01M, with a high of $-153.16M and a low of $-158.78M. This is -315.21% lower than Exact Sciences's previous annual EBITDA (Sep 23) of $72.03M.
Exact Sciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 15 | 7 | 3 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 7 | 7 | 9 | 8 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $794.00K | $-81.03M | $-74.15M | $-127.75M | $-148.76M | $-166.06M | $-180.94M | $-220.61M | $-166.94M | $-176.91M | $-31.16M | $-436.81M | $-219.88M | $-86.14M | $-105.70M | $77.94M | $-40.46M |
| Avg Forecast | $27.98M | $36.82M | $31.70M | $-44.52M | $-680.60K | $7.21M | $-3.96M | $-54.00M | $-61.50M | $-36.20M | $-62.89M | $-225.07M | $-78.16M | $-87.12M | $-87.74M | $-204.61M | $-186.67M | $-197.94M | $-191.87M | $-186.01M | $-154.82M | $-155.97M | $-137.91M | $-51.19M | $-35.69M | $-98.74M | $-119.10M | $-84.20M | $-65.28M | $-75.00M |
| High Forecast | $30.77M | $40.49M | $34.86M | $-43.38M | $-663.11K | $7.93M | $-3.86M | $-25.71M | $-1.92M | $-35.27M | $-61.28M | $-180.06M | $-72.26M | $-59.90M | $-85.48M | $-163.69M | $-149.34M | $-197.94M | $-191.87M | $-148.81M | $-154.82M | $-155.97M | $-137.91M | $-40.95M | $-35.69M | $-98.74M | $-119.10M | $-67.36M | $-65.28M | $-75.00M |
| Low Forecast | $27.26M | $35.87M | $30.88M | $-48.96M | $-748.52K | $7.03M | $-4.36M | $-105.43M | $-122.99M | $-39.81M | $-69.17M | $-270.09M | $-91.43M | $-119.80M | $-96.49M | $-245.53M | $-224.01M | $-197.94M | $-191.87M | $-223.21M | $-154.82M | $-155.97M | $-137.91M | $-61.43M | $-35.69M | $-98.74M | $-119.10M | $-101.04M | $-65.28M | $-75.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01% | 0.92% | 0.36% | 0.68% | 0.75% | 0.87% | 0.97% | 1.42% | 1.07% | 1.28% | 0.61% | 12.24% | 2.23% | 0.72% | 1.26% | -1.19% | 0.54% |
Exact Sciences's average Quarter net income forecast for Dec 23 is $-78.16M, with a range of $-91.43M to $-72.26M. EXAS's average Quarter net income forecast represents a -9943.24% decrease compared to the company's last Quarter net income of $794.00K (Sep 23).
Exact Sciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 15 | 7 | 3 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 7 | 7 | 9 | 8 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $390.55M | $414.45M | $404.26M | $404.11M | $379.70M | $397.60M | $401.98M | $463.71M | $383.12M | $362.43M | $453.84M | $312.21M | $252.08M | $225.60M | $281.70M | $264.10M | $166.80M |
| Avg Forecast | $698.39M | $680.31M | $667.82M | $613.99M | $625.85M | $614.22M | $598.03M | $549.25M | $543.33M | $560.44M | $539.50M | $500.03M | $499.48M | $482.24M | $470.01M | $454.58M | $392.37M | $392.26M | $390.15M | $413.25M | $351.15M | $336.22M | $329.15M | $303.81M | $347.12M | $263.82M | $178.60M | $224.41M | $232.55M | $168.97M |
| High Forecast | $752.00M | $732.54M | $719.09M | $661.13M | $673.89M | $661.37M | $643.94M | $571.05M | $594.79M | $560.61M | $539.50M | $600.04M | $511.63M | $488.65M | $506.09M | $545.49M | $470.85M | $392.26M | $390.15M | $495.90M | $351.15M | $336.22M | $329.15M | $303.81M | $347.12M | $263.82M | $178.60M | $269.29M | $232.55M | $168.97M |
| Low Forecast | $684.58M | $666.86M | $654.62M | $601.86M | $613.48M | $602.08M | $586.21M | $540.86M | $532.00M | $560.27M | $539.50M | $400.03M | $493.51M | $476.68M | $460.72M | $363.66M | $313.90M | $392.26M | $390.15M | $330.60M | $351.15M | $336.22M | $329.15M | $303.81M | $347.12M | $263.82M | $178.60M | $179.52M | $232.55M | $168.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.88% | 0.89% | 1.03% | 0.97% | 1.02% | 0.97% | 1.32% | 1.14% | 1.10% | 1.49% | 0.90% | 0.96% | 1.26% | 1.26% | 1.14% | 0.99% |
Exact Sciences's average Quarter SG&A projection for Dec 23 is $499.48M, based on 7 Wall Street analysts, with a range of $493.51M to $511.63M. The forecast indicates a 27.89% rise compared to EXAS last annual SG&A of $390.55M (Sep 23).
Exact Sciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 15 | 7 | 3 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 7 | 7 | 9 | 8 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.45 | $-0.42 | $-0.72 | $-0.84 | $-0.94 | $-1.04 | $-1.28 | $-0.97 | $-1.03 | $-0.18 | $-2.79 | $-1.46 | $-0.58 | $-0.71 | $0.56 | $-0.31 |
| Avg Forecast | $0.15 | $0.20 | $0.17 | $-0.24 | $-0.00 | $0.04 | $-0.02 | $-0.29 | $-0.33 | $-0.20 | $-0.34 | $-0.47 | $-0.42 | $-0.47 | $-0.47 | $-0.73 | $-0.79 | $-1.07 | $-1.04 | $-1.10 | $-0.84 | $-0.85 | $-0.75 | $-0.96 | $-0.19 | $-0.54 | $-0.65 | $-0.58 | $-0.35 | $-0.41 |
| High Forecast | $0.17 | $0.22 | $0.19 | $-0.23 | $-0.00 | $0.04 | $-0.02 | $-0.14 | $-0.01 | $-0.19 | $-0.33 | $-0.46 | $-0.39 | $-0.32 | $-0.46 | $-0.71 | $-0.77 | $-1.07 | $-1.04 | $-1.10 | $-0.84 | $-0.85 | $-0.75 | $-0.96 | $-0.19 | $-0.54 | $-0.65 | $-0.58 | $-0.35 | $-0.41 |
| Low Forecast | $0.15 | $0.19 | $0.17 | $-0.26 | $-0.00 | $0.04 | $-0.02 | $-0.57 | $-0.67 | $-0.22 | $-0.37 | $-0.52 | $-0.49 | $-0.65 | $-0.52 | $-0.80 | $-0.87 | $-1.07 | $-1.04 | $-1.10 | $-0.84 | $-0.85 | $-0.75 | $-0.96 | $-0.19 | $-0.54 | $-0.65 | $-0.58 | $-0.35 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01% | 0.95% | 0.58% | 0.91% | 0.78% | 0.90% | 0.95% | 1.52% | 1.15% | 1.38% | 0.19% | 14.41% | 2.73% | 0.90% | 1.22% | -1.58% | 0.76% |
According to 7 Wall Street analysts, Exact Sciences's projected average Quarter EPS for Dec 23 is $-0.42, with a low estimate of $-0.49 and a high estimate of $-0.39. This represents a -9712.05% decrease compared to EXAS previous annual EPS of - (Sep 23).
Exact Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GH | Guardant Health | $30.21 | $57.27 | 89.57% | Buy |
| MYGN | Myriad Genetics | $15.68 | $29.00 | 84.95% | Hold |
| EXAS | Exact Sciences | $50.93 | $89.67 | 76.07% | Buy |
| CRL | Charles River Laboratories | $196.90 | $303.60 | 54.19% | Buy |
| ILMN | Illumina | $142.24 | $202.44 | 42.32% | Buy |
| CDNA | CareDx | $21.55 | $29.75 | 38.05% | Buy |
| CSTL | Castle Biosciences | $30.83 | $40.50 | 31.37% | Buy |
| DHR | Danaher | $239.38 | $305.47 | 27.61% | Buy |
| TMO | Thermo Fisher Scientific | $533.02 | $642.48 | 20.54% | Buy |
| A | Agilent | $130.22 | $152.64 | 17.22% | Buy |
| TWST | Twist Bioscience | $38.96 | $42.40 | 8.83% | Buy |
| NTRA | Natera | $151.11 | $120.92 | -19.98% | Buy |